Triazine derivatives as interferon-gamma inhibitors
US10576086B2 · kind B2 · utility
0Cited by
5References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 10, 2016 |
| Grant date | Mar 3, 2020 |
| Priority date | — |
| Expiry date | Jun 10, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to interferon-gamma (IFN-γ) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-γ production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.